跳至主要内容
临床试验/NCT04281511
NCT04281511已完成不适用

A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy

National Cancer Center, Korea1 个研究点 分布在 1 个国家目标入组 238 人开始时间: 2019年4月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
238
试验地点
1
主要终点
median survival

研究概览

简要总结

  1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center.
  2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center

详细描述

  1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample
  2. Collect data of Biomarker for pancreatic cancer
  3. Compare with Big data and Cohort study in National cancer center
  4. The number of subjects is changed by statistical consideration. 218->238

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Pathologically Confirmed Pancreatic Cancer Patients

排除标准

  • Subjects who do not agree with the study

结局指标

主要结局

median survival

时间窗: 5 years

The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse

progressive-free survival

时间窗: 5 years

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Sang Myung Woo

Chief, Senior Scientist

National Cancer Center, Korea

研究点 (1)

Loading locations...

相似试验